Trial · NCT07902726
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
NCT07902726, Phase 2, Not yet recruiting, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes. Trials, record NCT07902726. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902726
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
- NCT number
- NCT07902726
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University Health Network, Toronto
- Conditions
- T2D
- Interventions
- Acetazolamide 62.5 mg, Acetazolamide 125 mg, Acetazolamide 250 mg, Dapagliflozin 10mg
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Iohexol Measured GFR | From baseline to the end of treatment at 16 weeks | The primary outcome of this study is the absolute change in measured GFR during each 2-week course of acetazolamide, while on background dapagliflozin therapy. GFR will be measured using plasma clearance of the iohexol contrast agent. The initial "dip" in GFR was selected as the primary outcome as it provides an early and measurable indicator of the treatment effect on kidney physiology. A transient reduction in GFR is a known physiological response to both acetazolamide and SGLT2i, reflecting their effects on hyperfiltration. Assessing this early change allows evaluation of the immediate physiological response to combination therapy but also acts as an indicator of the potential longer-term renal benefits. |
| Secondary | Measured GFR Recovery | From baseline to the end of treatment at 16 weeks | Measured GFR through iohexol clearance will be used to determine GFR recovery to baseline following each washout period. |
| Secondary | eGFR | From baseline to the end of treatment at 16 weeks | Measured using spot urine and FMV urine collection for serum creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation. |
| Secondary | Urine Albumin-to-Creatinine (UACR) | From baseline to the end of treatment at 16 weeks | UACR will be quantified by measuring albumin and creatinine excretion using the average of three FMV samples. |
| Secondary | Systolic Blood Pressure | From baseline to the end of treatment at 16 weeks. | Systolic blood pressure will be measured as per Hypertension Canada and assessed using an automated vital signs monitor (Connex Vital Signs Monitor, Welch Allyn). |
| Secondary | Diastolic Blood Pressure | From baseline to the end of treatment at 16 weeks | Diastolic blood pressure will be measured as per Hypertension Canada and assessed using an automated vital signs monitor (Connex Vital Signs Monitor, Welch Allyn). |
| Secondary | Change in Body Weight | From baseline to the end of treatment at 16 weeks | |
| Secondary | Mean Arterial Pressure | From baseline to the end of treatment at 16 weeks | Mean blood pressure will be measured as per Hypertension Canada and assessed using an automated vital signs monitor (Connex Vital Signs Monitor, Welch Allyn). |
| Secondary | Percent Fat Mass | From baseline to the end of treatment at 16 weeks | Bioimpedance analysis will be performed to determine percent body fat. |
| Secondary | Percent Extracellular Fluid | From baseline to the end of treatment at 16 weeks | Bioimpedance analysis will be performed to determine the percent extracellular fluid. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902726
GET https://conductscience.org/api/trials/v1/NCT07902726/registered